Toxoplasmosis among Patients with Cancers and Blood Disorders in Iran: Serological Evaluation, Risk Factors and Comparison with Healthy Individuals

Journal of Chemical Health Risks

دوره 11، شماره 3، آذر 2021، صفحه 271-282   

نوع مقاله: Original Article

شناسه دیجیتال (DOI): 10.22034/jchr.2021.1922691.1257

نویسندگان

Muhammad I Getso¹؛ Vahid Raissi²؛ Maryam Fasihi Karami³؛ Gita Alizadeh²؛ Mohammad Zareie⁴؛ Zahra Babaei Samani⁵؛ Fatemeh bayat²؛ Omid Raiesi⁶؛ Soodabeh Etemadi^{* 7، 8}

¹Department of Medical Microbiology and Parasitology, College of Health Sciences, Bayero University Kano PMB 3011 Kano-Nigeria

²Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

³Department of Medical Parasitology and Mycology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁴Department of Basic Sciences of Veterinary Medicine, Kazerun branch, Islamic Azad University, Kazerun, Iran

⁵DVM student at faculty of Veterinary Medicine, Shahrekord university, shahrekord, Iran

⁶Department of Medical Parasitology and Mycology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran

⁷Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran

⁸Department of Medical Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

چکیده

Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis in humans and warm-blooded animals. In this study, we explored the risk factors and seroprevalence of Toxoplasma infection among cancer patients and patients with blood cell disorders in Iran. We collected serum samples from each participant  include  600 clinically healthy individuals, 127 patients with different types of cancer, 294 patients with red blood cell disorders, and 101 patients with white blood cell disorders and tested for anti-Toxoplasma antibodies (IgG and IgM) using an Enzyme-Linked Immunosorbent Assay kits and analyzed the results statistically.Out of the 1122 participants ,seroprevalence of Toxoplasmosis among all patients with different disorders , patients with white blood cell disorders, patients with red blood cell disorders and patients with different types of cancer 9.97% , 17.82%, 11.57% and  7.09% were reported  respectiveiy.Awareness campaign to educate blood cell disorders patients regarding contact with pets is salient to the reduction of the Toxoplasma burden. In addition, it is pertinent to screen patients with cancers to rule out Toxoplasma infections. 

کلیدواژه‌ها

Toxoplasmosis؛ Cancer؛ Blood disorders؛ Epidemiology؛ Iran

مراجع

1. Zadeh A.E., Bamedi T., Etemadi S., Shahrakipour M., Saryazdipour K., 2014. Toxoplasmosis as a complication of transfusion in hemodialysis patients. Iran J Ped Hematol Oncol. 4(1), 22-25   

 

 

 

2. Eskandarian A., Jahani S., Hejazi H., Yousefi H., Raissi V., 2017. Investigation of toxoplasma gondii infection in Cutaneous Leishmaniasis patients of the Isfahan province. Int J Infect. 1,4(2),.1-5.

3. Karami M.F., Rafiei A., Raiesi O., Getso M., Akhlaghi E., Jalali P., Shayanfard M., Beigzadeh E., Arbat S.K., Mirabedini Z., Raissi V., 2019. The Relation between Toxocariasis and Toxoplasmosis co-infection and the presence of Rheumatoid Factor (RF) in people with hydatidosis in Southwestern Iran, from 2013 to 2018. J Parasit Dis. 43(3), 379-384.

4. Fenta H.M., Workie D.L., Zike D.T., Taye  B.W. , Swain P.K., 2020. Determinants of stunting among under-five years children in Ethiopia from the 2016 Ethiopia demographic and Health Survey: Application of ordinal logistic regression model using complex sampling designs. Clin Epidemiol Glob Health. 8(2),404-413.

5. CDC A., 2014. Parasites-Toxoplasmosis (Toxoplasma infection). Am J Trop Med Hyg . 9(1), 794-799.

6. Wang Z.D., Liu H.H., Ma Z.X., Ma H.Y., Li Z.Y., Yang Z.B., Zhu X.Q., Xu B., Wei F., Liu Q., 2017. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol. 9(8), 389-396.

7. Sharif A.A., Aliyu M., Yusuf M.A., Getso M.I., Yahaya H., Bala J.A., Yusuf I., Wana M.N., 2018. Risk factors and mode of transmission of toxoplasmosis in Nigeria: a review. BAJOPAS . 11(2), 107-121.

8. Raissi V., Taghipour A., Navi Z., Etemadi S., Sohrabi Z., Sohrabi N., Getso M., Shamsaei S., Fasihi Karami M., Raiesi O., 2020. Seroprevalence of Toxoplasma gondii and Toxocara spp. infections among pregnant women with and without previous abortions in the west of Iran. J Obstet Gynaecol Res.46(3), 382-388.

9. Eroglu S., Asgin N., 2020. Awareness, knowledge and risk factors of Toxoplasma gondii infection among pregnant women in the Western Black Sea region of Turkey. J Obstet Gynaecol .2(8), 1-7.

10. Joob B., Wiwanitkit V., 2019. Toxoplasmosis in Cancer Patients and Suggestion for Screening. Asian Pac J Cancer Prev. 20(4), 985-986.

11. Plata J.D., Castañeda X., 2020. Parasites in Cancer Patients. Oncol Crit Care. 1441-1450.

12. Malek R.A., Wassef R., Rizk E., Sabry H., Tadros N., Boghdady A., 2018. Toxoplasmosis an overlooked disease: seroprevalence in cancer patients. Asian Pac J Cancer Prev. 19(7),1987-1992.

13. Saki J., Tavakoli S., Pedram M., 2017. Seroprevalence and molecular evaluation of toxoplasmosis in children with cancer in Khuzestan province, Southwest of Iran. J Parasit Dis. 41(4), 947-951.

14. Ahmadpour  E., Daryani  A., Sharif  M., Sarvi S., Aarabi  M., Mizani  A., Rahimi  M.T., Shokri  A., 2014. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries. 8(12),1503-1510.

15. Arefkhah N., Hosseini  S.A., Karimzade R., Moshfe A., Hadinia F., Larki R.A., Mozaffari M.A.N., Hadinia A., 2019. Seroprevalence and risk factors of Toxoplasma gondii infection among cancer and hemodialysis patients in southwest Iran. Clin Epidemiol Glob Health. 7(4),596-599.

16. Foroutan-Rad M., Khademvatan S., Majidiani H., Aryamand S., Rahim F., Malehi A.S., 2016. Seroprevalence of Toxoplasma gondii in the Iranian pregnant women: a systematic review and meta-analysis. Acta Trop .158, 160-169.

17. Walle F., Kebede N., Tsegaye A., Kassa T., 2013. Seroprevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia.  Parasit Vectors. 6(1),1-8.

18. Adurthi S., Sahoo T.P., Chakka K., Radhika B., Appaji L., Bapsy P.P., Ramesh C., Jayshree R.S., 2008. Acute toxoplasmosis in nonstem cell transplant patients with haematological malignancies: a study from a regional cancer institute in South India.  Hematol. Oncol. 26(4), 229-233.

19. Siegel S.E., Lunde M.N., Gelderman A.H., Halterman R.H., Brown J.A., Levine A.S., Graw J.R., 1971. Transmission of toxoplasmosis by leukocyte transfusion. Blood. 37(4),388-394.

20. Pedram M., Maraghi S., Soltani Shirazi A., Jaseb K., Haghi S., 2013. A report of two cases of cerebral toxoplasmosis in leukemia patients. Jundishapur J Microbiol. 6(10), 235-250

21. Abedalthagafi M., Rushing E.J., Garvin D., Cheson B., Ozdemirli M., 2010. Asymptomatic diffuse “encephalitic” cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature. Int J Clin Exp Pathol. 3(1), 106-109

22. Bacchu S., Fegan C.,  Neal J., 2007.Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine. Br J Haematol. 139(3), 349-349.

23. Huang Y., Huang Y., Chang A., Wang J., Zeng X., Wu J., 2016. Is Toxoplasma gondii infection a risk factor for leukemia? An evidence-based meta-analysis. Med Sci Mon Int Med J Exp Clin Res. 22, 1547-1552.

24. Kalantari N., Rezanejad J., Tamadoni A., Ghaffari S., Alipour J., Bayani M., 2018. Association between Toxoplasma gondii exposure and paediatrics haematological malignancies: a case–control study.                Epidemiol Infect. 146(15),1896-1902.

25. Chaves-Carballo E., Efthimiadis B.K., Stockwell H.P., 1976. Toxoplasmosis After Splenectomy in Sickle Cell Disease: Report of Two Cases with Recurrence in One Child Two Years Following Antitoxoplasmic Therapy. Clin Pediatr.15(3), 270-272.

26. Rahimi Z., 2013. Genetic epidemiology, hematological and clinical features of hemoglobinopathies in Iran. BioMed Res Int. 2013(3) 1-10

27. Payandeh M., Rahimi Z., Zare M.E., Kansestani A.N., Gohardehi F., Hashemian A.H., 2014. The prevalence of anemia and hemoglobinopathies in the hematologic clinics of the kermanshah province, Western iran. Int J Hematol Oncol Stem Cell Res . 8(2), 33-37

28. Moghimi M., Doosti M., Vahedian-Ardakani H.A., Talebi A., Akhavan-Ghalibaf  M., Najafi A., Aminorroaya M.M., Yazdani S., Shayestehpour M., Bahrami H., Khodayari F., 2015. Serological study on cytomegalovirus and Toxoplasma gondii in thalassemia major patients of Yazd, Iran. Iran J Ped Hematol Oncol.  5(3), 150-155.

29. Hanifehpour H., Shariat S.K.S., Ghafari M.S., Kheirandish F., Saber V., Fallahi S., 2019. Serological and molecular diagnosis of Toxoplasma gondii infections in thalassemia patients. Iran J Parasitol. 14(1), 20-24.

30. El-Tantawy N., Darwish A., Eissa E., 2019. Seroprevalence of Toxoplasma gondii Infection Among Β-Thalassemia Major Pediatric Population: Implications for Transfusion Transmissible Toxoplasmosis. Pediatr Infect Dis. J. 38(3), 236-240.

31. Saleh A.Y.,Al-Numan A.Y.S., 2019. Investigation of the incidence of Toxoplasmosis and cytomegalovirus in patients with thalassemia. TikritJ Pure Sci. 23(10), 14-18.

32. Karakas S., Özlem S., Tellioglu A.M, Ertabaklar H., Ertug S., 2012. Investigation of Anti-Toxoplasma gondii IgG and IgM Antibodies in Beta Thalaseamia Major Patients in Aydin Province. Turkiye Parazitol Derg.  36(3), 133-136.

33. Ferreira M.N., Bonini-Domingos C.R., Estevão I.F., de Castro Lobo C.L., Carrocini G.C.S., Silveira-Carvalho A.P., Ricci O., De Mattos L.C.de Mattos C.C.B., 2017. Anti-Toxoplasma gondii antibodies in patients with beta-hemoglobinopathies: the first report in the Americas. BMC Res Notes. 10(1), 1-7.

 

 

 

 

 

 

 

 

 

 

34. Anvari D., Sharif M., Sarvi S, Aghayan S.A., Gholami S., Pagheh A.S., Hosseini S.A., Saberi R., Chegeni T.N., Hosseininejad Z., Daryani A., 2019. Seroprevalence of Toxoplasma gondii infection in cancer patients: a systematic review and meta-analysis. Microb Pathog. 129, 30-42.

35. Yazar S., Yaman O., Eser B., Altuntaş F., Kurnaz F., Şahin I., 2004. Investigation of anti-Toxoplasma gondii antibodies in patients with neoplasia. J Med Microbiol. 53(12), 1183-1186.

36. Molan A.L., Rasheed E.H., 2016. Study the possible link between toxoplasmosis and different kinds of cancer in Iraq. Am J Life Sci Res. 4(3),110-116

37. Cong W., Liu G.H., Meng Q.F., Dong W., Qin S.Y., Zhang F.K., Zhang X.Y., Wang X.Y., Qian A.D., Zhu X.Q., 2015. Toxoplasma gondii infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. Cancer Lett. 359(2), 307-313.

38. Mostafa N.E.S., Hamed E.F.A., Rashed H.E.S., Mohamed S.Y., Abdelgawad M.S., Elasbali A.M., 2018. The relationship between toxoplasmosis and different types of human tumors. J Infect Dev Ctries. 12(2),137-141.